MIR1910: A Drug Target / Disease Biomarker (G100302261)
MIR1910: A Drug Target / Disease Biomarker
MIR1910, also known as interleukin-18 (IL-18), is a protein that is expressed in a variety of tissues throughout the body. It is a key regulator of immune and inflammatory responses, and has been implicated in a number of diseases, including cancer, autoimmune disorders, and obesity.
One of the main functions of IL-18 is its role in the regulation of immune responses. IL-18 is produced by monocytes and dendritic cells in the immune system, and it travels to the site of an infection or injury to help stimulate an immune response. When IL-18 is present in the body, it can help to coordinate the actions of different immune cells and promote the production of antibodies and other immune molecules.
IL-18 is also involved in the regulation of inflammation. When tissue is damaged or infected, IL-18 is produced and helps to coordinate the inflammatory response. This can include the production of white blood cells, such as neutrophils, which are critical for fighting off infections.
One of the ways that IL-18 contributes to inflammation is by promoting the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines help to recruit additional immune cells to the site of inflammation and promote the production of other pro-inflammatory molecules.
The potential clinical applications of IL-18 are numerous. For example, it has been shown to be a potential therapeutic target for a number of diseases, including cancer, autoimmune disorders, and obesity. In cancer, IL-18 has been shown to promote the growth and survival of cancer cells, and it has also been shown to be downregulated in the tissues of many cancer patients. Therefore, targeting IL-18 with drugs or other therapeutic approaches may be a promising strategy for the treatment of cancer.
In autoimmune disorders, IL-18 is involved in the development of inflammation and autoimmune responses. For example, in rheumatoid arthritis, IL-18 is produced by the immune system and contributes to the development of inflammation and joint damage. Therefore, blocking IL-18 with drugs or other therapeutic approaches may be a promising strategy for the treatment of autoimmune disorders.
In obesity, IL-18 is involved in the regulation of metabolism and energy homeostasis. For example, studies have shown that IL-18 is produced by the obese and that it promotes the production of fat cells. Therefore, targeting IL-18 with drugs or other therapeutic approaches may be a promising strategy for the treatment of obesity.
In conclusion, IL-18 is a protein that plays a critical role in the regulation of immune and inflammatory responses. It is involved in the regulation of immune responses, inflammation, and metabolism, and has been implicated in a number of diseases, including cancer, autoimmune disorders, and obesity. Therefore, targeting IL-18 with drugs or other therapeutic approaches may be a promising strategy for the treatment of these diseases.
Protein Name: MicroRNA 1910
More Common Targets
MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909
